Review of: "Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review"
Carlton J Spotswood
February 1, 2026 DOI: 10.32388/wzdtgt (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Population | Alcohol use disorder patients |
| Topics | Addiction Psilocybin |
| Keywords | Abstinence Disease |
| Key findings | Psilocybin-assisted therapy may reduce alcohol consumption and support abstinence in alcohol use disorder, but more controlled trials are needed. |
Abstract
Things to consider: .In the intro: "The so-called magic mushrooms from which psychedelics are extracted were traditionally absorbed by South-American peoples." This is clunky and I suspect it is due to translation errors; consider changing it. .In the intro: "In 1998, Dr. Heffter nally discovered a psychedelic active substance and named it mescaline." This was rst published in 1897, not 1998. .Consider describing why psychedelics weren't studied again until 1990, due to the Federal Controlled Substances Act of 1970, which was for DMT-not psilocybin. .Materials and methods -"biodisponsibility". .Same section -unclear why much of this was included. .Data sources section -psilocybin for the cure of AUD.I don't think "cure" is the word you are looking for. .There are concerns between my numbers #6 and #8, but I did not delve into them at this time. .Section 3.3 Adverse effects; "So far, it is reasonable to conclude that psilocybin does not induce psychedelic effects at clinically tested doses (25mg/70kg)." This is not accurate.and dangerous, leading people to believe that this is a low dose.as this is the dose that produces robust psychedelic effects.See -https://www.technologynetworks.com/neuroscience/news/psilocybin-is-safe
Comparable studies
Other narrative reviews on psilocybin for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| Psychedelics as anti-inflammatory agents Animal models and cellular studies | 2018 | Review | |
| Psychedelic Drugs in Biomedicine | 2017 | Review | |
| DARK Classics in Chemical Neuroscience: Psilocybin | 2018 | Review | |
| Psilocybin for treating substance use disorders? | 2016 | Narrative review |